|                                | All (n=1001) | Death within 3 months (n=146) | Survivors upon 3 months (n=855) | p-value |
|--------------------------------|--------------|-------------------------------|---------------------------------|---------|
| Female sex, N (%)              | 527 (52.6%)  | 85 (58.2%)                    | 442 (51.7%)                     | 0.169*  |
| Age, median (IQR)              | 75 (65-82)   | 81 (74-86)                    | 75 (64-81)                      | <0.001* |
| **Functional impairment**      |              |                               |                                 |         |
| Admission NIHSS, median, IQR, n=1001 | 16 (11-21) | 21 (16-24)                    | 15 (10-20)                      | <0.001* |
| pmRS, median, IQR, n=1000      | 1 (0-2)      | 2 (1-3)                       | 1 (0-2)                         | <0.001* |
| Preexisting functional impairment (pmRS>1), N (%), n=1001 | 349 (34.9) | 86 (58.9)                     | 263 (30.8)                      | <0.001* |
| 3-month mRS, median, IQR, n=1001 | -            | -                             | 3 (1-4)                         | -       |
| **Comorbidities**              |              |                               |                                 |         |
| Hypertension, N (%), n=971     | 750 (74.9%)  | 124 (84.9%)                   | 626 (73.2%)                     | 0.011*  |
| Diabetes, N (%), n=973         | 215 (21.5%)  | 43 (29.5%)                    | 172 (20.1%)                     | 0.021*  |
| Hypercholesterolemia, N (%)    | 343 (34.2%)  | 49 (33.6%)                    | 294 (34.4%)                     | 0.903*  |
| Coronary heart disease, N (%)  | 261 (26.1%)  | 53 (36.3%)                    | 208 (24.3%)                     | 0.001*  |
| AF, N (%), n=977               | 485 (48.5%)  | 95 (65.1%)                    | 390 (45.6%)                     | <0.001* |
| Previous stroke, N (%), n=970  | 201 (20.1%)  | 43 (29.5%)                    | 158 (18.5%)                     | 0.003*  |
| BP systolic, mean, SD, n=904   | 160 (27)     | 158 (29)                      | 160 (27)                        | 0.461*  |
| **Medical treatment**          |              |                               |                                 |         |
| Antiplatelets at baseline, N (%) | 320 (32.0) | 49 (30.1)                     | 271 (31.7)                      | 0.585*  |
| OAC at baseline, N (%), n=966  | 184 (18.4%)  | 42 (28.8%)                    | 142 (16.6%)                     | 0.001*  |
| Statin at baseline, N (%), n=951 | 292 (29.2) | 44 (30.1)                     | 248 (29.0)                      | 0.752*  |
| Additional thrombolysis, N (%) | 612 (61.1%)  | 88 (60.3%)                    | 524 (61.3%)                     | 0.817*  |
| **Renal function**             |              |                               |                                 |         |
| Baseline creatinine, mean (SD), n=1001 | 1.00 (0.37) | 1.04 (0.41)                   | 0.99 (0.37)                     | 0.146*  |
| Baseline GFR, mean (SD), n=1001 | 71.2 (29.9) | 69.1 (56.4)                   | 71.5 (22.4)                     | 0.337*  |
| Baseline renal impairment (eGFR<60 at admission), N (%), n=1001 | 315 (31.5) | 59 (40.4)                     | 256 (29.9)                      | 0.012*  |
| PC-AKI, N (%), n=1001           | 21 (2.1)     | 7 (4.8)                       | 14 (1.6)                        | 0.014*  |
| **Neuroradiological parameters** |              |                               |                                 |         |
| Anterior circulation stroke, N (%), n=1001 | 924 (92.3) | 138 (94.5)                    | 786 (91.9)                      | 0.278*  |
| Vessel occlusion, n=1001 | 77 (7.7) | 8 (5.5) | 69 (8.1) |
|---------------------------|---------|---------|----------|
| **Posterior circulation stroke, N (%), n=1001** | 77 (7.7) | 8 (5.5) | 69 (8.1) |
| **MCA, N (%)** | 598 (59.7) | 79 (54.1) | 519 (60.7) | 0.174* |
| **Carotid-T, N (%)** | 163 (16.3) | 46 (31.5) | 117 (13.6) | 0.174* |
| **ICA and MCA, N (%)** | 106 (10.6) | 4 (2.7) | 102 (11.8) | 0.174* |
| **ICA, N (%)** | 45 (4.5) | 8 (5.5) | 37 (4.3) |
| **BA, N (%)** | 74 (7.4) | 8 (5.5) | 66 (7.7) |
| **VA, N (%)** | 1 (0.1) | - | 1 (0.1) |
| **other, N (%)** | 14 (1.4) | 1 (0.7) | 13 (1.5) |
| **ASPECTS score, median, IQR, n=938** | 9 (7-10) | 8 (7-10) | 9 (7-10) | 0.016$^\text{§}$ |
| **TICI 2b-3 recanalization, N (%), n=886** | 819 (81.8) | 101 (69.2) | 718 (84.0) | <0.001* |
| **Failed recanalization (TICI 0-2a), N (%), n=886** | 182 (18.2) | 45 (30.8) | 137 (15.9) |
| **Any ICH after treatment, N (%), n=1001** | 300 (30.0) | 52 (35.6) | 248 (29.0) | 0.107* |
| **sICH after treatment, N (%), n=966** | 38 (3.8) | 11 (7.5) | 27 (3.2) | 0.015* |

**Supplementary Table 5: Clinical characteristics concerning three-month mortality.** All survivors of the acute hospital stay with available three-month outcome data were considered (n=1001).

IQR, interquartile range; SD, standard deviation; (p)mRS, (premorbid) modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; BP, blood pressure; OAC oral anticoagulation; eGFR, estimated glomerular filtration rate; PC-AKI, post-contrast acute kidney injury; MCA, middle cerebral artery; ICA, internal cerebral artery; BA, basilar artery; VA, vertebral artery; ASPECTS, Alberta Stroke Program Early CT Score; TICI, Thrombolysis In Cerebral Infarction; (s)ICH, (symptomatic) intracerebral hemorrhage. *unpaired t-test, § Mann Whitney U test, # chi square test. P-values ≤0.5 are displayed in bold.